Health AI Central
Peer-Reviewed Publication
Cancer Res Commun2026October 8, 2026Journal Article

Phase 1a Evaluation of LP-184 in Recurrent Glioblastoma: Safety, Pharmacokinetics, and Translational Optimization of CNS Exposure.

Karisa C Schreck1, Bachchu Lal2, Jianli Zhou3, Hernando Lopez-Bertoni4, Matthias Holdhoff5, Reginald Ewesuedo6, Kishor Bhatia7, Marc Chamberlain6, John Laterra4
1Johns Hopkins Medicine Baltimore, MD United States.
2Kennedy Krieger Institute Baltimore, MD United States.
3Lantern Pharma Inc. United States.
4Johns Hopkins University School of Medicine Baltimore, MD United States.
5Johns Hopkins Medicine Baltimore, Maryland United States.
6Lantern Pharma Inc. Dallas, TX United States.
7Lantern Pharma Inc. Dallas, Texas United States.
PubMed DOI

Abstract

PURPOSE: Limited central nervous system (CNS) bioavailability and pharmacodynamics are obstacles to effective systemic therapies for glioblastoma (GBM). One strategy to overcome these challenges is drug combinations enhancing CNS penetration and/or tumor chemosensitivity. LP-184 (zirdafulven), a synthetic acylfulvene class alkylator, induces DNA damage and inhibits glioblastoma cell viability in p…

Create a free account to keep reading

Free members get 10 full research views every month across publications, clinical trials, FDA clearances, adverse events, and NIH grants. No credit card required.

Create Free AccountSign In

Want unlimited research access? See Pro plans

Data Accuracy Notice: Research intelligence on Health AI Central is aggregated from public sources (PubMed, ClinicalTrials.gov, FDA, NIH, CMS, and others) and refreshed nightly. Classifications and derived metrics are produced by automated methods described in our Methodology. We recommend verifying critical data points against the primary sources before making decisions.